Australia - English - Department of Health (Therapeutic Goods Administration)

cutera australia pty ltd - 47883 - dermatological nd:yag laser system - intended for use in medical and cosmetic procedures in the specialties of dermatology, plastic surgery, and aesthetic medicine. specific indications: -treatment of mild to severe inflammatory acne (acne vulgaris) -treatment of acne scars -treatment of sebaceous hyperplasia

United States - English - NLM (National Library of Medicine)

kindred biosciences, inc. - dipyrone (unii: 6429l0l52y) (metamizole - unii:934t64rmnj) - horses with hypersensitivity to dipyrone should not receive zimeta. due to the prolongation of prothrombin time (pt) and associated clinical signs of coagulopathy, dipyrone should not be given more frequently than every 12 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

cutera australia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

cutera australia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

orthopaedic appliances pty ltd -

United States - English - NLM (National Library of Medicine)

kindred biosciences, inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirataz™ is contraindicated in cats with a known hypersensitivity to mirtazapine or to any of the excipients. mirataz™ should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor (maoi) [e.g. selegiline hydrochloride (l-deprenyl), amitraz], as there may be an increased risk of serotonin syndrome.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol tablets, usp is indicated for the long-term management of patients with angina pectoris. nadolol tablets, usp is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pre